Why the study?
The relevance of the uric acid to HDL-cholesterol ratio in hypertrophic cardiomyopathy, particularly in distinguishing obstructive from non-obstructive forms, remains unknown.
Does the uric acid/HDL-cholesterol ratio (UHR) differentiate obstructive from non-obstructive hypertrophic cardiomyopathy?
Does the uric acid/HDL-cholesterol ratio (UHR) differentiate obstructive from non-obstructive hypertrophic cardiomyopathy?
The uric acid/HDL-cholesterol ratio may serve as a potential biomarker to distinguish obstructive from non-obstructive hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
UHR may help identify obstruction in HCM; leaves open its diagnostic role pending prospective validation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kunak et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: